相关实验视频
Updated: Sep 9, 2025
05:14
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
4.8K
心脏衰竭和排泄率降低的患者的数字毒素
Udo Bavendiek1, Anika Großhennig2, Johannes Schwab3,4
1Department of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
The New England journal of medicine
|August 29, 2025
概括
在减少喷射分数的患者中,滴毒素治疗显著降低了死亡或心力衰竭住院的综合风险. 这项研究确立了数字毒素作为治疗心力衰竭的潜在疗法.
科学领域:
- 心脏病学
- 药理学
- 临床试验
背景情况:
- 作为心脏糖化物,数字毒素在治疗心力衰竭的有效性尚未得到证实.
- 指导医学治疗 (GDMT) 是HFrEF的标准,但需要额外的治疗.
研究的目的:
- 在接受GDMT的HFrEF患者中,与安慰剂相比,评估数字毒素的治疗效果.
- 评估数字毒素对死亡率和心力衰竭住院的影响.
主要方法:
- 在一项国际双盲,安慰剂对照试验中,有1240名HFrEF患者随机接受数字毒素或安慰剂.
- 患者左心室喷射分数≤40% (NYHA III- IV类) 或≤30% (NYHA II类).
- 主要结局是因所有原因死亡或因心力衰竭恶化而入院.
主要成果:
- 在修改后的治疗意向群体 (1212名患者) 中,数位素降低了18%的初级综合结果 (危险比,0. 82;P=0. 03).
- 在36个月的中位数中,数字毒素显示出降低全因死亡率 (HR,0. 86) 和心力衰竭住院率 (HR,0. 85) 的趋势.
- 在数字毒素组中,严重不良事件发生的频率更高 (4. 7% 与 2. 8% 相比).
结论:
- 在接受GDMT的HFrEF患者中,滴毒素治疗显著降低了死亡或心力衰竭住院的综合风险.
- 数字毒素是治疗心力衰竭的潜在治疗方案.
- 进一步的研究可能会探索最佳剂量和长期安全性.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
717
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
717
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:30Cardiomyopathy II: Dilated Cardiomyopathy
21
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
21
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434